Testing effectiveness (Phase 2)Ended earlyNCT01673672
What this trial is testing
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
Who this might be right for
Moderate to Severe Allergic Asthma
Cytos Biotechnology AG 365